EP0088606B1 - Monoclonal antibodies against lens epithelial cells - Google Patents
Monoclonal antibodies against lens epithelial cells Download PDFInfo
- Publication number
- EP0088606B1 EP0088606B1 EP83301176A EP83301176A EP0088606B1 EP 0088606 B1 EP0088606 B1 EP 0088606B1 EP 83301176 A EP83301176 A EP 83301176A EP 83301176 A EP83301176 A EP 83301176A EP 0088606 B1 EP0088606 B1 EP 0088606B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lens epithelial
- epithelial cells
- cells
- human lens
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000001542 lens epithelial cell Anatomy 0.000 title claims description 42
- 210000004027 cell Anatomy 0.000 claims description 32
- 208000002177 Cataract Diseases 0.000 claims description 15
- 101001007419 Homo sapiens Lens epithelial cell protein LEP503 Proteins 0.000 claims description 14
- 102000055233 human LENEP Human genes 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 210000004989 spleen cell Anatomy 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 9
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000002159 anterior chamber Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 206010036346 Posterior capsule opacification Diseases 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 208000008516 Capsule Opacification Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000012998 Hepes-buffered hanks’ balanced salt solution Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000003293 antilymphocyte serum Anatomy 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- These monoclonal antibodies specific to lens epithelial cells are produced by fusing human lens epithelial antibody producing cells with myeloma cells to provide a fused hybrid, the hybrid is cultured, and the antibodies specific to human lens epithelial cells are collected.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/355,081 US4432751A (en) | 1982-03-05 | 1982-03-05 | Monoclonal antibodies against lens epithelial cells and preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
| US355081 | 1982-03-05 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP0088606A2 EP0088606A2 (en) | 1983-09-14 |
| EP0088606A3 EP0088606A3 (en) | 1984-03-28 |
| EP0088606B1 true EP0088606B1 (en) | 1987-07-29 |
Family
ID=23396159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP83301176A Expired EP0088606B1 (en) | 1982-03-05 | 1983-03-04 | Monoclonal antibodies against lens epithelial cells |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4432751A (cs) |
| EP (1) | EP0088606B1 (cs) |
| JP (2) | JPS58192831A (cs) |
| CA (1) | CA1209500A (cs) |
| DE (1) | DE3372785D1 (cs) |
| DK (1) | DK160562C (cs) |
| GR (1) | GR77941B (cs) |
| IE (1) | IE54702B1 (cs) |
| IL (1) | IL69715A (cs) |
| ZA (1) | ZA831168B (cs) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202252A (en) * | 1982-03-05 | 1993-04-13 | Houston Biotechnology Inc. | Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
| EP0256344B1 (de) * | 1986-08-18 | 1992-04-22 | Wolfgang G.K. Dr. Müller-Lierheim | Kontaktlinse |
| US5616122A (en) * | 1986-11-04 | 1997-04-01 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
| US5055291A (en) * | 1986-11-04 | 1991-10-08 | Baylor College Of Medicine | Compositions for preventing secondary cataracts |
| NO173974C (no) * | 1986-11-04 | 1994-03-02 | Baylor College Medicine | Fremgangsmaate ved fremstilling av en cytotoksisk blanding |
| US4871350A (en) * | 1986-11-04 | 1989-10-03 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
| US4918165A (en) * | 1987-07-16 | 1990-04-17 | Ophthalmic Research Corporation | Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction |
| US4966577A (en) * | 1988-03-16 | 1990-10-30 | Allergan, Inc. | Prevention of lens-related tissue growth in the eye |
| US4909784A (en) * | 1988-03-25 | 1990-03-20 | Seymour Dubroff | Method for preventing clouding of posterior capsule after extracapsular cataract eye surgery |
| ATE126530T1 (de) * | 1988-06-08 | 1995-09-15 | Baylor College Medicine | Monoklonale antikörper gegen linsenepithelzellen und methoden zur verhinderung des vermehrung übriggebliebener linsenepithelzellen nach extrakapsuläres extraktion. |
| DE3826399C2 (de) * | 1988-08-03 | 2001-08-30 | Wilhelm Ludwig Kraemer | Reinigungsanlage für Waagen, insbesondere Kombinationswaagen |
| US5627162A (en) * | 1990-01-11 | 1997-05-06 | Gwon; Arlene E. | Methods and means for control of proliferation of remnant cells following surgery |
| JPH0555847U (ja) * | 1992-01-13 | 1993-07-27 | 三菱農機株式会社 | 脱穀機の受網目詰まり防止装置 |
| US5375611A (en) * | 1993-01-26 | 1994-12-27 | Pharmacia Ab | Method for preventing secondary cataract |
| US5876438A (en) * | 1993-08-02 | 1999-03-02 | Houston Biotechnology Incorporated | Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract |
| US5620013A (en) * | 1994-10-21 | 1997-04-15 | American Cyanamid Company | Method for destroying residual lens epithelial cells |
| CA2187482A1 (en) * | 1995-10-13 | 1997-04-14 | Eri Inoue | Pharmaceutical composition |
| US6106554A (en) * | 1999-02-25 | 2000-08-22 | Bausch & Lomb Surgical, Inc. | Intraocular lens implants for the prevention of secondary cataracts |
| US6454802B1 (en) | 2000-08-21 | 2002-09-24 | Bausch & Lomb Incorporated | Intraocular lens implant for the prevention of secondary cataracts |
| US6945971B1 (en) * | 2004-07-19 | 2005-09-20 | Gwon Arlene E | Controlled ocular lens regeneration |
| US7252662B2 (en) * | 2004-11-02 | 2007-08-07 | Lenticular Research Group Llc | Apparatus and processes for preventing or delaying one or more symptoms of presbyopia |
| US9649224B2 (en) | 2005-02-19 | 2017-05-16 | Lenticular Research Group Llc | Apparatus and processes for preventing or delaying onset or progression of age-related cataract |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307082A (en) * | 1979-07-10 | 1981-12-22 | New York University | Method for the extraction of a factor that mediates contact inhibition of cell growth |
| US4342828A (en) * | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4349528A (en) * | 1979-11-21 | 1982-09-14 | The Wistar Institute | Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen |
-
1982
- 1982-03-05 US US06/355,081 patent/US4432751A/en not_active Expired - Lifetime
-
1983
- 1983-02-22 ZA ZA831168A patent/ZA831168B/xx unknown
- 1983-02-24 DK DK084783A patent/DK160562C/da not_active IP Right Cessation
- 1983-03-04 GR GR70670A patent/GR77941B/el unknown
- 1983-03-04 EP EP83301176A patent/EP0088606B1/en not_active Expired
- 1983-03-04 JP JP58034699A patent/JPS58192831A/ja active Granted
- 1983-03-04 DE DE8383301176T patent/DE3372785D1/de not_active Expired
- 1983-03-04 CA CA000422956A patent/CA1209500A/en not_active Expired
- 1983-03-04 IE IE467/83A patent/IE54702B1/en not_active IP Right Cessation
- 1983-09-13 IL IL69715A patent/IL69715A/xx not_active IP Right Cessation
-
1992
- 1992-07-14 JP JP4187160A patent/JPH0751063B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IE54702B1 (en) | 1990-01-17 |
| ZA831168B (en) | 1983-11-30 |
| JPS58192831A (ja) | 1983-11-10 |
| IL69715A (en) | 1988-06-30 |
| US4432751A (en) | 1984-02-21 |
| JPH0751063B2 (ja) | 1995-06-05 |
| DK160562C (da) | 1991-09-02 |
| DK84783D0 (da) | 1983-02-24 |
| DK84783A (da) | 1983-09-06 |
| IE830467L (en) | 1983-09-05 |
| JPH0537B2 (cs) | 1993-01-05 |
| GR77941B (cs) | 1984-09-25 |
| DK160562B (da) | 1991-03-25 |
| EP0088606A2 (en) | 1983-09-14 |
| EP0088606A3 (en) | 1984-03-28 |
| DE3372785D1 (en) | 1987-09-03 |
| JPH05184358A (ja) | 1993-07-27 |
| CA1209500A (en) | 1986-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0088606B1 (en) | Monoclonal antibodies against lens epithelial cells | |
| Glaser et al. | Prolieferative vitreoretinopathy: the mechanism of development of vitreoretinal traction | |
| Coulombre et al. | The skeleton of the eye: I. Conjunctival papillae and scleral ossicles | |
| Yamamoto | Growth of lens and ocular environment: role of neural retina in the growth of mouse lens as revealed by an implantation experiment | |
| Rungger-Brändle et al. | Bilateral acute retinal necrosis (BARN): identification of the presumed infectious agent | |
| UA44729C2 (uk) | Спосіб інгібування ангіогенезу в тканині, спосіб інгібування ангіогенезу в твердій пухлині, спосіб індукції регресії твердої пухлинної тканини, спосіб інгібування росту твердої пухлинної тканини, спосіб зменшення кровопостачання тканини, спосіб інгібування ангіогенезу у запаленій, ангіогенній тканині, спосіб лікування пацієнтів (варіанти) | |
| NO159883B (no) | Monoklonalt antistoff. | |
| JP2002515036A (ja) | α▲下Ｖ▼β▲下５▼媒介血管形成の抑制に有用な方法および組成物 | |
| Kivelä et al. | Ezrin, a membrane-organizing protein, as a polarization marker of the retinal pigment epithelium in vertebrates | |
| Choi et al. | Effects of amniotic membrane suspension in the rat alkali burn model | |
| Khodadoust et al. | Induction of corneal graft rejection by passive cell transfer. | |
| NO820248L (no) | Fremgangsmaate ved fremstilling av monoklone antistoffer og celler istand til aa produsere slike antistoffer | |
| EA002986B1 (ru) | Применение фактора роста нервов для хранения, продуцирования и лечения роговицы и конъюнктивы | |
| Saika et al. | Osteopontin: a component of matrix in capsular opacification and subcapsular cataract | |
| Sotozono et al. | Oral mucosal epithelial transplantation and limbal-rigid contact lens: a therapeutic modality for the treatment of severe ocular surface disorders | |
| Gwon et al. | Induction of de novo synthesis of crystalline lenses in aphakic rabbits | |
| WO2004083382A2 (en) | Compositions and methods for treating hyperimmune response in the eye | |
| US5202252A (en) | Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction | |
| Ehrlich et al. | The effects of anti-cornea and anti-heart serum on cultured cells of rabbit cornea and other tissues | |
| Grisanti et al. | Xenotransplantation of retinal pigment epithelial cells into RCS rats | |
| Saika et al. | Collagenous deposits on explanted intraocular lenses | |
| Klintworth et al. | Recurrence of Lattice corneal LystLophy type 1 in the Corneal Grafts of two Siblings | |
| CN113559121B (zh) | 一种用于角膜移植免疫排斥反应治疗的药物 | |
| Forrester et al. | Corneal Transplantation: An Immunological Guide to the Clinical Problem (with CD-ROM) | |
| Pfeiffer et al. | Transfer of experimental panophthalmitis in rats by parabiosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT LI LU NL |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT LI LU NL |
|
| 17P | Request for examination filed |
Effective date: 19840511 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB IT LI LU NL |
|
| REF | Corresponds to: |
Ref document number: 3372785 Country of ref document: DE Date of ref document: 19870903 |
|
| ITF | It: translation for a ep patent filed | ||
| ET | Fr: translation filed | ||
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| ITTA | It: last paid annual fee | ||
| EPTA | Lu: last paid annual fee | ||
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20020306 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20020312 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20020315 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20020319 Year of fee payment: 20 Ref country code: DE Payment date: 20020319 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20020328 Year of fee payment: 20 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20020527 Year of fee payment: 20 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20030303 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20030303 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20030303 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20030304 Ref country code: LU Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20030304 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Effective date: 20030303 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| BE20 | Be: patent expired |
Owner name: *BAYLOR COLLEGE OF MEDICINE Effective date: 20030304 |
|
| NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |